	US 11,866,483 B2
	Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells
Yohei Kono, Yonago (JP); Noriko Itaba, Tottorishi (JP); and Goshi Shiota, Tottorishi (JP)
Assigned to KanonCure, Inc., Yonago (JP); and National University Corporation Tottori University, Tottori (JP)
Appl. No. 16/972,285
Filed by KanonCure, Inc., Yonago (JP); and National University Corporation Tottori University, Tottorishi (JP)
PCT Filed May 30, 2019, PCT No. PCT/JP2019/021603 § 371(c)(1), (2) Date Dec. 4, 2020, PCT Pub. No. WO2019/235362, PCT Pub. Date Dec. 12, 2019.
Claims priority of application No. 2018-110587 (JP), filed on Jun. 8, 2018.
Prior Publication US 2021/0115112 A1, Apr. 22, 2021
Int. Cl. A61K 38/00 (2006.01); C07K 14/81 (2006.01); C12N 5/0775 (2010.01); A61K 35/28 (2015.01)

CPC C07K 14/8146 (2013.01) [A61K 35/28 (2013.01); C12N 5/0663 (2013.01); A61K 38/00 (2013.01)]

6 Claims

1. A method of producing a composition having high fibrosis inhibitory effect comprising the steps of:

i) culturing bone marrow mononuclear cells or mesenchymal stem cells in a culture medium containing IC-2 or an analogous compound thereof for at least 9 days, characterized in that the concentration of IC-2 or the analogous compound thereof is maintained throughout the cultivation;

ii) collecting cultured cells, secreted products of the cells or both from the culture obtained in the step i); and

iii) recovering proteins from the cultured cells, the secreted products of the cells or the both collected in the step ii)

wherein said composition comprises MMP-1, MMP-14, MMP-2, MMP-13, and thioredoxin (TRX).